# BioAegis Therapeutics > BioAegis Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company at the NJ Bioscience Center in North Brunswick, New Jersey, developing recombinant human plasma gelsolin (rhu-pGSN) — a protein replacement therapy for diseases driven by excess inflammation. BioAegis runs no developer program and publishes no product API. The only machine-readable surface it exposes without credentials is the WordPress REST content API behind its website, described below. ## What this company is - Founded 2011; privately held; clinical stage. Headquarters: NJ Bioscience Center, 685 US Route 1, North Brunswick, NJ 08902. - Platform: plasma gelsolin (pGSN), an abundant naturally occurring human blood protein that keeps inflammation localized to the site of injury and boosts the innate immune system's ability to clear pathogens. The therapeutic is the recombinant human form, rhu-pGSN, supplementing depleted levels rather than suppressing immunity. - Founding science: the late Dr. Thomas P. Stossel (Harvard Medical School / Brigham and Women's Hospital), who discovered gelsolin. BioAegis holds an exclusive worldwide license from Brigham and Women's Hospital and more than 40 issued patents. - Lead programme: BTI-203, a randomized, double-blind, placebo-controlled Phase 2 study of rhu-pGSN added to standard of care in moderate-to-severe ARDS (P/F ratio <= 150) caused by infection. 600 patients, 75 sites, 13 countries (US, Canada, UK and EU). Primary endpoint: survival without organ failure at Day 28. Supported by BARDA DRIVe contract 75A50123C00067 ($20M). - Second programme: Phase 2 in inflammasome-driven decompression sickness (DCS), under a U.S. Navy Office of Naval Research contract awarded to the University of Maryland School of Medicine. - FDA Fast Track designation granted for both ARDS and DCS. - Announced April 2026: a collaboration with Prenosis to advance AI-driven precision medicine in inflammatory disease. ## What this company does NOT publish - No developer portal, no API documentation, no API reference, no getting-started guide. - No OpenAPI, AsyncAPI, GraphQL SDL, Postman collection or JSON Schema document set. - No SDKs, no CLI, no packages on npm/PyPI/Maven/NuGet/RubyGems/crates.io. - No MCP server, no A2A agent card, no webhooks, no event stream. - No security.txt, no vulnerability-disclosure policy, no bug bounty, no trust center, no published certifications. - No status page, no SLA, no API changelog, no rate-limit documentation. - No llms.txt of its own. ## The one machine-readable surface BioAegis Therapeutics Content API — the anonymously readable WordPress REST API behind the corporate site. This is the site's own content surface, not a product the company markets. - Base URL: https://www.bioaegistherapeutics.com/wp-json - Contract: no provider OpenAPI. An API Evangelist derivation covering the 23 anonymously verified operations is in this repository at openapi/bioaegis-therapeutics-content-openapi.yml. - Upstream contract definition: https://developer.wordpress.org/rest-api/ - Authentication: none required for reads. The REST index advertises WordPress application passwords, but the authorization endpoint sits behind wp-admin and is not obtainable by a third party. - Rate limits: none published. A Sucuri CloudProxy WAF fronts the origin and may throttle without advertising a budget. - Robots: /robots.txt permits everything (`User-agent: *`, empty `Disallow:`). Crawling is explicitly allowed. ### What it holds - 153 posts — 94 News press releases (2011 to April 2026), 34 Publications, 9 Events, 6 clinical advisory board profiles, 5 leadership profiles, 4 board profiles, 2 feature entries, 1 COVID-19 entry. - 14 pages — Home, About Us, Our Science, Our Platform, BTI-203 Clinical Trial, FAQs, Publications, News, Careers, Contact Us, Expanded Access Policy, Code of Ethics/Conduct, Terms of Use, Privacy Policy. - 247 media items. - 10 categories. Zero tags — the `post_tag` taxonomy is registered but empty. - Full prose: unlike many WordPress corporate sites, `content.rendered` and `excerpt.rendered` ARE populated on both posts and pages. ### Useful calls - Company identity as structured data: `GET /wp-json/yoast/v1/get_head?url=https%3A%2F%2Fwww.bioaegistherapeutics.com%2F` — returns the schema.org JSON-LD @graph under `json.schema['@graph']`. - Press releases newest first: `GET /wp-json/wp/v2/posts?categories=11&per_page=20&_fields=id,slug,title,link,date,modified` - Publications: `GET /wp-json/wp/v2/posts?categories=12&per_page=100&_fields=id,title,link,date` - Leadership and board: categories 7 (Leadership), 25 (Board), 5 (Clinical). - Clinical trial page: `GET /wp-json/wp/v2/pages/4401` - Full-text search: `GET /wp-json/wp/v2/search?search=gelsolin` — 137 matches. - Change detection: `GET /wp-json/wp/v2/posts?_fields=id,modified&orderby=modified&order=desc&per_page=1` ### Traps - ALWAYS send `_fields`. `content.rendered` is populated and page 5753 (Our Platform) alone returns ~100KB of rendered Elementor markup; an unfiltered `per_page=100` is a multi-megabyte response. - `per_page` is capped at 100. Values outside 1-100 return 400 `rest_invalid_param`. - Totals live only in headers — `X-WP-Total`, `X-WP-TotalPages` and RFC 8288 `Link`. The body is a bare array with no envelope. - `author` is a dead foreign key. /wp/v2/users returns 403 from the Sucuri WAF as an HTML page, not JSON, so authorship cannot be resolved and `_embed` on the author relation returns an error stub. Branch on Content-Type before parsing any error body. - Errors are the WordPress `{code, message, data.status}` envelope, not RFC 9457 problem+json. WordPress returns 401 (not 403) for capability refusals to anonymous callers, so retry-with-credentials logic will loop. - No ETag, Last-Modified or Cache-Control. Conditional requests are impossible; use each object's `modified` field. - The `yoast/v1/get_head` operation exists only because the Yoast SEO plugin is installed. It would vanish without notice if the plugin were changed. - The WordPress Abilities API (`wp-abilities/v1`), an agent-facing capability registry, IS registered on this deployment — but every endpoint under it returns 401 anonymously. There is no usable agent surface here. ## Repository artifacts - openapi/bioaegis-therapeutics-content-openapi.yml — derived OpenAPI 3.1.0, 23 operations - overlays/bioaegis-therapeutics-content-overlay.yaml — API Evangelist enhancements - authentication/bioaegis-therapeutics-authentication.yml — auth profile, probed - conventions/bioaegis-therapeutics-conventions.yml — pagination, projection, caching, error envelope - errors/bioaegis-therapeutics-problem-types.yml — 15 error codes, provoked live - data-model/bioaegis-therapeutics-data-model.yml — entity graph, including the broken author arc - lifecycle/bioaegis-therapeutics-lifecycle.yml — versioning, deprecation, status, changelog (all absent) - conformance/bioaegis-therapeutics-conformance.yml — standards assertions with evidence - json-ld/bioaegis-therapeutics-organization.jsonld — the provider's own schema.org graph, verbatim - well-known/bioaegis-therapeutics-well-known.yml — /.well-known/ probe results (all 404) - security/bioaegis-therapeutics-domain-security.yml — TLS/HSTS/DNSSEC/CAA/SPF/DMARC probe - skills/ — packaged agent skills for the flows above ## Company links - Website: https://www.bioaegistherapeutics.com/ - About: https://www.bioaegistherapeutics.com/about-us/ - Our Science: https://www.bioaegistherapeutics.com/our-science/ - Our Platform: https://www.bioaegistherapeutics.com/our-platform/ - BTI-203 Clinical Trial: https://www.bioaegistherapeutics.com/bti-203-clinical-trial/ - Publications: https://www.bioaegistherapeutics.com/publications-plasma-gelsolin/ - FAQs: https://www.bioaegistherapeutics.com/faqs/ - News: https://www.bioaegistherapeutics.com/news-plasma-gelsolin/ (RSS: /feed/) - Careers: https://www.bioaegistherapeutics.com/careers/ - Contact: https://www.bioaegistherapeutics.com/contact-us/ - Expanded Access Policy: https://www.bioaegistherapeutics.com/expanded-access-policy/ - Code of Ethics/Conduct: https://www.bioaegistherapeutics.com/code-of-ethics-conduct/ - Terms of Use: https://www.bioaegistherapeutics.com/terms-of-use/ - Privacy Policy: https://www.bioaegistherapeutics.com/privacy-policy/ - LinkedIn: https://www.linkedin.com/company/bioaegis-therapeutics - X: https://twitter.com/bioaegis - YouTube: https://www.youtube.com/channel/UC9AflH4d_CL1TZLTBwb21HA